Problems of psychological assistance to patients with neurofibromatosis type I
Abstract
Neurofibromatosis type I is one of the most common hereditary tumor syndromes and is characterized by the development of multiple skin and subcutaneous tumors on the body, disfiguring the appearance of patients. The literature search strategy on psychological care for patients with neurofibromatosis type I included searching for relevant articles in Scopus, Web of Science, and PubMed. Half of patients with neurofibromatosis type I develop plexiform neurofibromas, which can compress internal organs, deform the face or limbs, and impair self-care and social adaptation. Surgical methods are used to treat cutaneous and subcutaneous neurofibromas, but the number of these tumors is increasing, causing serious psychological trauma to patients. In this regard, common problems of patients with neurofibromatosis type I, in addition to tumor damage, are psychological disorders such as anxiety, depression, and distress. These disorders worsen the quality of life of patients and require qualified psychological assistance. This article examines the nature and frequency of psychological disorders in patients with neurofibromatosis type I, as well as problems associated with the availability of psychological assistance. Measures are proposed for the timely identification of distress, anxiety and depression in patients and their treatment with routing for consultations with the necessary specialists. An analysis of the scientific literature shows a lack of publications in the field of research into the psychological problems of patients with neurofibromatosis type I compared to cancer patients. Future directions of research in this area should involve active involvement of department staff, psychotherapists and psychologists in the examination of patients with neurofibromatosis type I throughout the world.
Copyright (c) 2025 Author(s)
This work is licensed under a Creative Commons Attribution 4.0 International License.
References
1. Lee TSJ, Chopra M, Kim RH, et al. Incidence and prevalence of neurofibromatosis type 1 and 2: a systematic review and meta-analysis. Orphanet Journal of Rare Diseases. 2023; 18(1). doi: 10.1186/s13023-023-02911-2
2. Crow AJD, Janssen JM, Marshall C, et al. A systematic review and meta‐analysis of intellectual, neuropsychological, and psychoeducational functioning in neurofibromatosis type 1. American Journal of Medical Genetics Part A. 2022; 188(8): 2277-2292. doi: 10.1002/ajmg.a.62773
3. Ly KI, Blakeley JO. The Diagnosis and Management of Neurofibromatosis Type 1. Medical Clinics of North America. 2019; 103(6): 1035-1054. doi: 10.1016/j.mcna.2019.07.004
4. Miraglia E, Moliterni E, Iacovino C. Cutaneous manifestations in neurofibromatosis type 1. La Clinica Terapeutica. 2020; (5): 371-377. doi: 10.7417/CT.2020.2242
5. Glombova M, Petrak B, Lisy J, et al. Brain gliomas, hydrocephalus and idiopathic aqueduct stenosis in children with neurofibromatosis type 1. Brain and Development. 2019; 41(8): 678-690. doi: 10.1016/j.braindev.2019.04.003
6. Lim Z, Gu TY, Tai BC, et al. Survival outcomes of malignant peripheral nerve sheath tumors (MPNSTs) with and without neurofibromatosis type I (NF1): a meta-analysis. World Journal of Surgical Oncology. 2024. doi: 10.1186/s12957-023-03296-z
7. Wu F, Ji X, Shen M, et al. Prevalence, clinical characteristics and outcomes of seizures in neurofibromatosis type 1: A systematic review and single arm meta-analysis. Epilepsy Research. 2024; 208: 107476. doi: 10.1016/j.eplepsyres.2024.107476
8. Wang D, Zhang B, Wen X, et al. Clinical features and surgical treatments of scoliosis in neurofibromatosis type 1: a systemic review and meta-analysis. European Spine Journal. 2024; 33(7): 2646-2665. doi: 10.1007/s00586-024-08194-w
9. Virdis R, Street ME, Bandello MA, et al. Growth and pubertal disorders in neurofibromatosis type 1. Journal of Pediatric Endocrinology and Metabolism. 2003.
10. Armand ML, Taieb C, et al. Burden of adult neurofibromatosis 1: development and validation of a burden assessment tool. Orphanet Journal of Rare Diseases. 2019; 14(1). doi: 10.1186/s13023-019-1067-8
11. Bottesi G, Spoto A, Trevisson E, et al. Dysfunctional coping is related to impaired skin‐related quality of life and psychological distress in patients with neurofibromatosis type 1 with major skin involvement. British Journal of Dermatology. 2019; 182(6): 1449-1457. doi: 10.1111/bjd.18363
12. Maresca G, Bonanno C, Veneziani I, et al. The Lack of Ad Hoc Neuropsychological Assessment in Adults with Neurofibromatosis: A Systematic Review. Journal of Clinical Medicine. 2024; 13(5): 1432. doi: 10.3390/jcm13051432
13. Kenborg L, Andersen EW, Duun‐Henriksen AK, et al. Psychiatric disorders in individuals with neurofibromatosis 1 in Denmark: A nationwide register‐based cohort study. American Journal of Medical Genetics Part A. 2021; 185(12): 3706-3716. doi: 10.1002/ajmg.a.62436
14. Wiener L, Battles H, Bedoya SZ, et al. Identifying Symptoms of Distress in Youth Living with Neurofibromatosis Type 1 (NF1). Journal of Genetic Counseling. 2017; 27(1): 115-123. doi: 10.1007/s10897-017-0128-1
15. Granström S, Langenbruch A, Augustin M, et al. Psychological Burden in Adult Neurofibromatosis Type 1 Patients: Impact of Disease Visibility on Body Image. Dermatology. 2012; 224(2): 160-167. doi: 10.1159/000337548
16. Lai JS, Jensen SE, Charrow J, et al. Patient Reported Outcomes Measurement Information System and Quality of Life in Neurological Disorders Measurement System to Evaluate Quality of Life for Children and Adolescents with Neurofibromatosis Type 1 Associated Plexiform Neurofibroma. The Journal of Pediatrics. 2019; 206: 190-196. doi: 10.1016/j.jpeds.2018.10.019
17. Rietman AB, van Helden H, Both PH, et al. Worries and needs of adults and parents of adults with neurofibromatosis type 1. American Journal of Medical Genetics Part A. 2018; 176(5): 1150-1160. doi: 10.1002/ajmg.a.38680
18. Liang W, Cao S, Suo Y, et al. Long-term distress throughout one’s life: health-related quality of life, economic and caregiver burden of patients with neurofibromatosis type 1 in China. Frontiers in Public Health; 2024. doi: 10.3389/fpubh.2024.1398803
19. Seligman ME. Flourish: A Visionary New Understanding of Happiness and Well-Being. New York: Simon and Schuster; 2012.
20. Mustafin RN. Prospects for the treatment of neurofibromatosis type 1: A review. Journal of Modern Oncology. 2022; 24(2): 209-215. doi: 10.26442/18151434.2022.2.201431
21. Han Y, Li B, Yu X, et al. Efficacy and safety of selumetinib in patients with neurofibromatosis type 1 and inoperable plexiform neurofibromas: a systematic review and meta-analysis. Journal of Neurology. 2024; 271(5): 2379-2389. doi: 10.1007/s00415-024-12301-8
22. Mustafin RN. Questions on surgical treatment of neurofibromatosis type 1. Russian Journal of Pediatric Hematology and Oncology. 2022; 9(2): 54-59. doi: 10.21682/2311-1267-2022-9-2-54-59
23. Jeong SY, Park SJ, Kim HJ. The Spectrum of NF1 Mutations in Korean Patients with Neurofibromatosis Type 1. Journal of Korean Medical Science. 2006; 21(1): 107. doi: 10.3346/jkms.2006.21.1.107
24. Pros E, Gómez C, Martín T, et al. Nature and mRNA effect of 282 differentNF1point mutations: focus on splicing alterations. Human Mutation. 2008; 29(9): E173-E193. doi: 10.1002/humu.20826
25. Evlice A, Bişgin A, Koç F. Neurological comorbidities and novel mutations in Turkish cases with neurofibromatosis type 1. Ideggyógyászati szemle. 2023; 76(7-8): 270-274. doi: 10.18071/isz.76.0270
26. Savad S, Modarressi MH, Younesi S, et al. A Comprehensive Overview of NF1 Mutations in Iranian Patients. NeuroMolecular Medicine; 2024. doi: 10.1007/s12017-024-08790-5
27. Fishbein NS, Vranceanu AM, Mace RA. Baseline characteristics of adults with neurofibromatosis enrolled on a psychosocial randomized controlled trial. Journal of Neuro-Oncology. 2022; 159(3): 637-646. doi: 10.1007/s11060-022-04104-6
28. Wang DL, Smith KB, Esparza S, et al. Emotional functioning of patients with neurofibromatosis tumor suppressor syndrome. Genetics in Medicine. 2012; 14(12): 977-982. doi: 10.1038/gim.2012.85
29. Bannon SM, Hopkins SW, Grunberg VA, et al. Psychosocial profiles of risk and resiliency in neurofibromatoses: a person-centered analysis of illness adaptation. Journal of Neuro-Oncology. 2022; 156(3): 519-527. doi: 10.1007/s11060-021-03928-y
30. Mace RA, Doorley J, Bakhshaie J, et al. Psychological resiliency explains the relationship between emotional distress and quality of life in neurofibromatosis. Journal of Neuro-Oncology. 2021; 155(2): 125-132. doi: 10.1007/s11060-021-03852-1
31. Doorley JD, Greenberg J, Bakhshaie J, et al. Depression explains the association between pain intensity and pain interference among adults with neurofibromatosis. Journal of Neuro-Oncology. 2021; 154(2): 257-263. doi: 10.1007/s11060-021-03826-3
32. Cohen JS, Levy HP, Sloan J, et al. Depression among adults with neurofibromatosis type 1: prevalence and impact on quality of life. Clinical Genetics. 2015; 88(5): 425-430. doi: 10.1111/cge.12551
33. Doser K, Andersen EW, Kenborg L, et al. Clinical characteristics and quality of life, depression, and anxiety in adults with neurofibromatosis type 1: A nationwide study. American Journal of Medical Genetics Part A. 2020; 182(7): 1704-1715. doi: 10.1002/ajmg.a.61627
34. Hamoy-Jimenez G, Kim R, Suppiah S, et al. Quality of life in patients with neurofibromatosis type 1 and 2 in Canada. Neuro-Oncology Advances; 2020;. doi: 10.1093/noajnl/vdaa003
35. Yamauchi T, Suka M. Quality of life in patients with neurofibromatosis type 1: a nationwide database study in Japan from 2015 to 2019. Environmental Health and Preventive Medicine. 2023; 28(0): 77-77. doi: 10.1265/ehpm.23-00221
36. Dance B, Dardare A, Fleming J, et al. The impact of cutaneous neurofibromas on quality of life and mental health in neurofibromatosis type 1. The Journal of Dermatology. 2024; 51(8): 1050-1059. doi: 10.1111/1346-8138.17276
37. Yoo HK, Porteous A, Ng A, et al. Impact of neurofibromatosis type 1 with plexiform neurofibromas on the health-related quality of life and work productivity of adult patients and caregivers in the UK: a cross-sectional survey. BMC Neurology; 2023. doi: 10.1186/s12883-023-03429-7
38. Tang PL, Wang HH, Chou FH. A Systematic Review and Meta-Analysis of Demoralization and Depression in Patients With Cancer. Psychosomatics. 2015; 56(6): 634-643. doi: 10.1016/j.psym.2015.06.005
39. Belzeaux R, Lançon C. Neurofibromatosis type 1: psychiatric disorders and quality of life impairment. Presse Med. 2006; 35(2): 277-80. doi: 10.1016/S0755-4982(06)74570-5
40. Berardelli I, Maraone A, Belvisi D, et al. The importance of suicide risk assessment in patients affected by neurofibromatosis. International Journal of Psychiatry in Clinical Practice. 2021; 25(4): 350-355. doi: 10.1080/13651501.2021.1921217
41. Lester EG, Wang KE, Blakeley JO, et al. Occurrence and Severity of Suicidal Ideation in Adults With Neurofibromatosis Participating in a Mind–Body RCT. Cognitive and Behavioral Neurology. 2023; 36(1): 19-27. doi: 10.1097/wnn.0000000000000332
42. Esposito M, Marotta R, Roccella M, et al. Pediatric neurofibromatosis 1 and parental stress: a multicenter study. Neuropsychiatric Disease and Treatment; 2014. doi: 10.2147/ndt.s55518
43. Al Ghriwati N, Little P, Martin S, et al. Parent-child discrepancies in reports of child psychosocial functioning in neurofibromatosis type 1. Journal of Family Psychology. 2025; 39(1): 99-106. doi: 10.1037/fam0001256
44. Buono FD, Sprong ME, Paul E, et al. The mediating effects of quality of life, depression, and generalized anxiety on perceived barriers to employment success for people diagnosed with Neurofibromatosis Type 1. Orphanet Journal of Rare Diseases. 2021; 16(1). doi: 10.1186/s13023-021-01866-6
45. Cipolletta S, Spina G, Spoto A. Psychosocial functioning, self‐image, and quality of life in children and adolescents with neurofibromatosis type 1. Child: Care, Health and Development. 2017; 44(2): 260-268. doi: 10.1111/cch.12496
46. Vranceanu AM, Merker VL, Plotkin SR, et al. The relaxation response resiliency program (3RP) in patients with neurofibromatosis 1, neurofibromatosis 2, and schwannomatosis: results from a pilot study. Journal of Neuro-Oncology. 2014; 120(1): 103-109. doi: 10.1007/s11060-014-1522-2
47. Talaei-Khoei M, Riklin E, Merker VL, et al. First use of patient reported outcomes measurement information system (PROMIS) measures in adults with neurofibromatosis. Journal of Neuro-Oncology. 2016; 131(2): 413-419. doi: 10.1007/s11060-016-2314-7
48. Martin S, Roderick MC, Lockridge R, et al. Feasibility and Preliminary Efficacy of an Internet Support Group for Parents of a Child with Neurofibromatosis Type 1: a Pilot Study. Journal of Genetic Counseling. 2016; 26(3): 576-585. doi: 10.1007/s10897-016-0031-1
49. Lester EG, Macklin EA, Plotkin S, et al. Improvement in resiliency factors among adolescents with neurofibromatosis who participate in a virtual mind-body group program. Journal of Neuro-Oncology. 2020; 147(2): 451-457. doi: 10.1007/s11060-020-03441-8
50. Zale EL, Pierre-Louis C, Macklin EA, et al. The impact of a mind-body program on multiple dimensions of resiliency among geographically diverse patients with neurofibromatosis. Journal of Neuro-Oncology. 2017; 137(2): 321-329. doi: 10.1007/s11060-017-2720-5
51. Wang KE, Vranceanu AM, Lester EG. Resiliency outcomes after participation in an asynchronous web-based platform for adults with neurofibromatosis: The NF-Web study. PLOS ONE. 2023; 18(12): e0295546. doi: 10.1371/journal.pone.0295546
52. Martin S, Wolters PL, Toledo‐Tamula MA, et al. Acceptance and commitment therapy in youth with neurofibromatosis type 1 (NF1) and chronic pain and their parents: A pilot study of feasibility and preliminary efficacy. American Journal of Medical Genetics Part A. 2016; 170(6): 1462-1470. doi: 10.1002/ajmg.a.37623
53. van Leeuwen JPA, Urganci Y, Ossewaarde L, et al. Treatment of emotion regulation problems in people with neurofibromatosis type 1 (Dutch). Tijdschr Psychiatr. 2024;66(6):331-335.
54. Depping MK, Uhlenbusch N, Härter M, et al. Efficacy of a Brief, Peer-Delivered Self-management Intervention for Patients With Rare Chronic Diseases. JAMA Psychiatry. 2021; 78(6): 607. doi: 10.1001/jamapsychiatry.2020.4783
55. Elkefi S, Trapani D, Ryan S. The role of digital health in supporting cancer patients’ mental health and psychological well-being for a better quality of life: A systematic literature review. International Journal of Medical Informatics. 2023; 176: 105065. doi: 10.1016/j.ijmedinf.2023.105065
56. Schellekens MP, van den Hurk DG, Prins JB, et al. Study protocol of a randomized controlled trial comparing Mindfulness-Based Stress Reduction with treatment as usual in reducing psychological distress in patients with lung cancer and their partners: the MILON study. BMC Cancer. 2014; 14(1). doi: 10.1186/1471-2407-14-3
57. Liu X, Sun L, Du X, et al. Reducing anxiety and improving self-acceptance in children and adolescents with osteosarcoma through group drawing art therapy. Frontiers in Psychology. 2023; 14. doi: 10.3389/fpsyg.2023.1166419
58. Merlin NM, Anggorowati A, Bagus Ropyanto C. The effects of quantum psychological relaxation technique on self-acceptance in patients with breast cancer. Canadian Oncology Nursing Journal. 2019; 29(4): 232-236. doi: 10.5737/23688076294232236
59. Brederecke J, Zimmermann T. Psychometric properties of the German version of the Self Image Scale (SIS-D) in a sample of cancer patients. PLOS ONE. 2020; 15(10): e0240619. doi: 10.1371/journal.pone.0240619
60. Walz B, Pfefferle V, Häfner HM, et al. Cosmetic and functional results after resection of cutaneous neurofibroma in neurofibromatosis type 1: Operation of neurofibroma improves quality of life while having moderate complications (German). Dermatologie (Heidelb); 2024. doi: 10.1007/s00105-023-05283-7
61. Taylor LA, Lewis VL. Neurofibromatosis Type 1: Review of Cutaneous and Subcutaneous Tumor Treatment on Quality of Life. Plastic and Reconstructive Surgery—Global Open. 2019; 7(1): e1982. doi: 10.1097/gox.0000000000001982
62. Katalinic D. Laser Surgery of Neurofibromatosis 1 (NF 1). Journal of Clinical Laser Medicine & Surgery. 1992; 10(3): 185-192. doi: 10.1089/clm.1992.10.185
63. Amaral FR, Ferreira MVL, Costa LAP, et al. Use of Surgical Laser for Excision of a Neurofibroma Associated With Neurofibromatosis Type-1. Journal of Lasers in Medical Sciences. 2018; 9(3): 219-222. doi: 10.15171/jlms.2018.39
64. Zhu B, Wei C, Wang W, et al. Treatment and progress of cutaneous neurofibroma. Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi. 2022; 36(9): 1064-1071. doi: 10.7507/1002-1892.202205072
65. Borgia P, Piccolo G, Santangelo A, et al. Dermatologic Effects of Selumetinib in Pediatric Patients with Neurofibromatosis Type 1: Clinical Challenges and Therapeutic Management. Journal of Clinical Medicine. 2024; 13(6): 1792. doi: 10.3390/jcm13061792
